Recent Updates — ZTS
The Board of Zoetis Inc. appointed Iris Knobloch as a director, increasing the board size from twelve to thirteen members effective December 1, 2026. Ms. Knobloch will serve on the Corporate Governance Committee and brings extensive experience in global consumer strategy, digital transformation, and public company governance from her roles at Deezer, Lazard, Vail Resorts, and WarnerMedia. She joins the board under standard compensation terms and indemnification agreements. Zoetis is the world’s leading animal health company that develops and distributes medicines, vaccines, diagnostics, and digital solutions for pets, livestock, and veterinarians.
The Board of Directors declared a quarterly cash dividend of $0.53 per share on Zoetis Inc.'s common stock. The payment is scheduled for December 1, 2026, to shareholders of record as of the close of business on October 30, 2026. This distribution reflects the company's ongoing commitment to returning capital to investors while funding its operations in the global animal health sector. Zoetis operates as the world’s leading animal health company, developing and commercializing medicines, vaccines, diagnostics, and digital solutions for pets, livestock, and poultry.
Zoetis Inc. appointed James Saccaro as Executive Vice President, Chief Financial Officer and Chief Operating Officer, effective August 17, 2026. Mr. Saccaro will lead the global finance function and oversee Global Manufacturing and Supply. He receives a $1,000,000 annual base salary, a target incentive of 100% of base salary, and a $5,000,000 annual long-term incentive opportunity. Additionally, he is granted a one-time make-whole award of restricted stock units valued at $6,250,000 and a cash payment of $1,250,000. Wetteny Joseph departs as CFO to become Special Advisor to the CEO until early 2027. Zoetis is the world's leading animal health company developing medicines, vaccines, diagnostics, and digital solutions for pets and livestock.
Zoetis Inc. reported second quarter 2026 financial results on August 6, 2026, revealing flat revenue of $2.47 billion and net income of $691 million, or $1.65 per diluted share. Adjusted net income was $781 million, or $1.87 per diluted share. The company cited pressured demand in the Companion Animal market due to lower clinic visits and price sensitivity, which drove a 7% decline in U.S. segment revenue. Conversely, International revenue grew 6% organically, supported by new product launches like Lenivia and Portela. Zoetis revised its full year 2026 guidance downward, lowering organic operational revenue growth expectations to (3)% to (1)% and adjusted diluted EPS to $6.15 - $6.25. The company also announced the acquisition of VitalRADS to expand its diagnostics capabilities. Zoetis operates in the animal health industry, developing and commercializing medicines, vaccines, and diagnostics for companion animals and livestock.